Deep Genomics

What it does

Deep Genomics is an AI-native drug discovery company applying deep learning to RNA biology - using AI to predict how genetic variants affect RNA splicing, gene expression, and protein production, and to design RNA-based therapeutic candidates (antisense oligonucleotides, siRNA) that correct these effects. Its BigRNA platform uses large language models trained on genomic data to predict the impact of any genetic change on RNA processing - enabling the discovery of genetic drivers of disease and design of RNA therapeutics targeting them. Deep Genomics both licenses its AI platform to pharmaceutical partners and runs its own internal pipeline of AI-designed RNA therapeutics.

Strengths

• Pharmaceutical companies and biotech firms partner with Deep Genomics for RNA therapeutics discovery - AI-powered genetic variant analysis identifying novel disease targets and AI therapeutic design generating candidate molecules for rare genetic diseases.
• Deep Genomics is an AI-native drug discovery company applying deep learning to RNA biology - using AI to predict how genetic variants affect RNA splicing, gene expression, and protein production, and to design RNA-based therapeutic candidates (antisense oligonucleotides, siRNA) that correct these effects.
• Its BigRNA platform uses large language models trained on genomic data to predict the impact of any genetic change on RNA processing - enabling the discovery of genetic drivers of disease and design of RNA therapeutics targeting them.

Watch-outs

• Highly specialized RNA biology focus: Deep Genomics is focused on RNA biology and RNA therapeutics — pharmaceutical companies working in small molecule, antibody, or gene editing modalities have limited applicable use cases for the platform.
• AI predictions require experimental validation: Deep Genomics' AI predicts RNA biology outcomes from sequence data but all therapeutic candidates require extensive experimental validation and clinical testing before any human use.
• Early-stage company with pipeline risk: Deep Genomics is an AI-native drug discovery company with an internal pipeline — the value realization timeline is long and subject to clinical development risk like any drug development program.

Pricing

Deep Genomics operates through pharmaceutical partnership deals and internal pipeline development. Partnership contracts are negotiated milestone-based agreements. Not a commercially available SaaS platform.